Shionogi & Co Ltd - Planned Acquisition Of Global Rights To Tanabe Pharma's RADICAVA ORS And IV RADIC
I'm PortAI, I can summarize articles.
Dec 22 (Reuters) - Shionogi & Co Ltd (4507.T) :SHIONOGI EXPANDS RARE DISEASE PRESENCE WITH PLANNED ACQUISITION OF GLOBAL RIGHTS TO TANABE PHARMA CORPORATION’S RADICAVA ORS (EDARAVONE) AND IV RADICTO PAY LUMP SUM OF $2.5 BILLION TO TANABE PHARMA UPON COMPLETION OF PROCEDURESMAY PAY A ROYALTY ON FUTURE SALES, SUBJECT TO CERTAIN CONDITIONSTRANSACTION EXPECTED TO BE IMMEDIATELY ACCRETIVE IN FY26, ADDING APPROXIMATELY USD 700 MILLION IN ANNUAL GLOBAL SALES Source text: Further company coverage: (4507.T)
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments